Nature Communications · 2018 · 45 citations · 41 references
PharmacyBiochemistryMedicinal ChemistryEnzyme MechanismEnzymologyMicrobial MetabolismCatalytic MechanismsCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesMetabolic Pathway ChemistryMicrobial Natural Product BiosynthesisBiosynthetic Pathway AnalysisCytochrome P450 Enzyme ActivityCytochrome P450 PathwaysDrug Metabolism Pathway AnalysisEnzyme BiosynthesisEnzyme FamiliesEnzyme Reaction Mechanisms
Rifamycin-derived drugs, including rifampin, rifabutin, rifapentine, and rifaximin, have long been used as first-line therapies for the treatment of tuberculosis and other deadly infections. However, the late steps leading to the biosynthesis of the industrially important rifamycin SV and B remain largely unknown. Here, we characterize a network of reactions underlying the biosynthesis of rifamycin SV, S, L, O, and B. The two-subunit transketolase Rif15 and the cytochrome P450 enzyme Rif16 are found to mediate, respectively, a unique C-O bond formation in rifamycin L and an atypical P450 ester-to-ether transformation from rifamycin L to B. Both reactions showcase interesting chemistries for these two widespread and well-studied enzyme families.
41
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text